BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 11550152)

  • 21. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.
    Shin DM; Glisson BS; Khuri FR; Lippman SM; Ginsberg L; Diaz E; Papadimitrakopoulou V; Feng L; Francisco M; Garden A; Kies MS; Myers J; Clayman G; Hong WK
    Cancer; 2002 Jul; 95(2):322-30. PubMed ID: 12124833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study.
    Caponigro F; Rosati G; De Rosa P; Avallone A; De Rosa V; De Lucia L; Comella P; Comella G
    Oncology; 2002; 63(3):232-8. PubMed ID: 12381902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
    Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
    Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I study of cabazitaxel in combination with platinum and 5-fluorouracil (PF) in locally advanced squamous cell carcinoma of head and neck (LA-SCCHN).
    Camille N; Rozehnal J; Roy E; Uczkowski D; Olson A; Genden E; Teng M; Bakst R; Gupta V; Posner M; Misiukiewicz K
    Oral Oncol; 2017 Aug; 71():99-104. PubMed ID: 28688700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study.
    Chang PM; Tzeng CH; Chen MH; Tsao CJ; Su WC; Hwang WS; Chang YF; Chang SY; Yang MH
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1477-84. PubMed ID: 21484308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.
    Dimery IW; Brooks BJ; Winn R; Martin T; Shirinian M; Hong WK
    J Clin Oncol; 1991 Nov; 9(11):1939-44. PubMed ID: 1941052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.).
    Galetta D; Giotta F; Rosati G; Gebbia V; Manzione L; Di Bisceglie M; Borsellino N; Colucci G
    Anticancer Res; 2005; 25(6C):4445-9. PubMed ID: 16334124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I study of a fixed dose of cisplatin with increasing doses of raltitrexed (Tomudex) in the treatment of patients with locally advanced or metastatic squamous cell carcinoma of the head and neck.
    ten Bokkel Huinink D; Tesselaar ME; Baatenburg de Jong RJ; Verschuur HP; Keizer HJ
    Ann Oncol; 2001 Mar; 12(3):357-63. PubMed ID: 11332149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: a multicenter phase II trial.
    Gebbia V; Mantovani G; Agostara B; Contu A; Farris A; Colucci G; Cognetti F; Restivo G; Speciale R; Ferrero B
    Ann Oncol; 1995 Dec; 6(10):987-91. PubMed ID: 8750150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma: a phase II trial.
    Baur M; Kienzer HR; Schweiger J; DeSantis M; Gerber E; Pont J; Hudec M; Schratter-Sehn AU; Wicke W; Dittrich C
    Cancer; 2002 Jun; 94(11):2953-8. PubMed ID: 12115384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cisplatin/Tegafur/Uracil/Irinotecan Triple Combination Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase I/II Clinical Study.
    Chen SC; Chang PM; Yang MH
    Oncologist; 2016 May; 21(5):537-8. PubMed ID: 27091418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of a combination of low-dose cisplatin with 13-cis-retinoic acid and interferon-alpha in patients with advanced head and neck squamous cell carcinoma.
    Gravis G; Pech-Gourgh F; Viens P; Alzieu C; Camerlo J; Oziel-Taieb S; Jausseran M; Maraninchi D
    Anticancer Drugs; 1999 Apr; 10(4):369-74. PubMed ID: 10378671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma.
    Kim HS; Kim HR; Kim GM; Kim HS; Koh YW; Kim SH; Choi EC; Hong YK; Sung JH; Kim SM; Kim JH; Cho BC
    Cancer Chemother Pharmacol; 2012 Oct; 70(4):539-46. PubMed ID: 22868340
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
    Soulières D; Faivre S; Mesía R; Remenár É; Li SH; Karpenko A; Dechaphunkul A; Ochsenreither S; Kiss LA; Lin JC; Nagarkar R; Tamás L; Kim SB; Erfán J; Alyasova A; Kasper S; Barone C; Turri S; Chakravartty A; Chol M; Aimone P; Hirawat S; Licitra L
    Lancet Oncol; 2017 Mar; 18(3):323-335. PubMed ID: 28131786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
    Worden FP; Moon J; Samlowski W; Clark JI; Dakhil SR; Williamson S; Urba SG; Ensley J; Hussain MH;
    Cancer; 2006 Jul; 107(2):319-27. PubMed ID: 16779801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of high-dose ifosfamide as a single agent and in combination with cisplatin in the treatment of advanced and/or recurrent squamous cell carcinoma of head and neck.
    Pai VR; Parikh DM; Mazumdar AT; Rao RS
    Oncology; 1993; 50(2):86-91. PubMed ID: 8451041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II study of paclitaxel and cisplatin combination chemotherapy in recurrent or metastatic head and neck cancer.
    Basaran M; Bavbek SE; Güllü I; Demirelli F; Sakar B; Tenekeci N; Altun M; Yalçin S; Onat H
    J Chemother; 2002 Apr; 14(2):207-13. PubMed ID: 12017379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ifosfamide in the treatment of head and neck cancer.
    Airoldi M; Cortesina G; Giordano C; Pedani F; Bumma C
    Oncology; 2003; 65 Suppl 2():37-43. PubMed ID: 14586145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical phase II evaluation of paclitaxel in combination with cisplatin in metastatic or recurrent squamous cell carcinoma of the head and neck.
    Thödtmann F; Theiss F; Kemmerich M; Heinrich B; Laubenbacher C; Quasthoff S; Kau R; Herzog M; Diergarten K; Hanauske AR
    Ann Oncol; 1998 Mar; 9(3):335-7. PubMed ID: 9602270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma.
    Clark JI; Hofmeister C; Choudhury A; Matz G; Collins S; Bastian R; Melian E; Emami B; Petruzzelli G
    Cancer; 2001 Nov; 92(9):2334-40. PubMed ID: 11745288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.